Evaluating the prognosis of severe toxoplasmosis in ICU patients
Official title: Prognosis of Disseminated and Cerebral Toxoplasmosis Hospitalized in Intensive Care in the Era of PCR Diagnosis - Toxoplasmosis in ICU (TOXIC)
Run by Assistance Publique - Hôpitaux de Paris · NCT06305468 · Data updated 2026-11-12
This study looks at how well different treatments work for patients with severe toxoplasmosis in the ICU, especially those with weakened immune systems, to understand their chances of recovery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris, France) |
| Status | Recruiting |
| Started | August 1, 2024 |
| Main results expected | April 1, 2026 |
| Study ends | April 1, 2026 |
| Registry record updated | January 28, 2025 |
| Trial ID | NCT06305468 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adult patients hospitalized in intensive care with at least one organ failure and a positive PCR for toxoplasmosis.
✕Probably not a fit
Patients who have a post-mortem diagnosis or whose primary outcome data is unavailable will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the prognosis of patients with severe toxoplasmosis who are hospitalized in intensive care units, particularly focusing on those with underlying immunosuppression. It will evaluate the impact of various anti-infective treatment regimens and identify clinical-biological and prognostic differences based on the type of immunosuppression. The study utilizes polymerase chain reaction (PCR) diagnostics to improve the accuracy of diagnosis and treatment response evaluation. By analyzing data from patients with disseminated and cerebral forms of toxoplasmosis, the study seeks to fill gaps in existing research regarding treatment efficacy and patient outcomes.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and better prognostic understanding for patients with severe toxoplasmosis.
How similar studies have gone: While there have been studies on toxoplasmosis, this specific focus on severe cases in ICU settings using PCR diagnostics is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient hospitalized in intensive care * At least 1 organ failure (SOFA\> or =2) * PCR toxoplasmosis on CSF, blood, BAL, or bone marrow positive within 7 days before or after admission to ICU Exclusion Criteria: * Post-mortem diagnosis * Primary outcome not available * Patient living informed and not opposed to the reuse of their data in this research.
Where it's running
-
Cochin hospital
Paris, France, France Recruiting
Study contacts
- Principal investigator: Clara Vigneron, MD — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Clara Vigneron, MD
- Email: clara.vigneron@aphp.fr
- Phone: 06 33 14 56 50
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood microRNAs to distinguish schizophrenia, depression, and bipolar disorder in women with chronic toxoplasmosis
This project will test whether specific blood microRNA levels can help tell apart schizophrenia, major depression, and bipolar disorder in women with long-term Toxoplasma gondii infection.
-
Treating congenital toxoplasmosis with specific medications
This study is testing the best way to use a combination of medications to treat congenital toxoplasmosis in infants and also looks at treating infected fetuses in pregnant women.
-
Characterizing cerebral toxoplasmosis in non‑HIV immunocompromised adults at Strasbourg University Hospital.
This project will collect clinical information on adults with weakened immune systems (excluding HIV) who have cerebral toxoplasmosis to see which diagnostic methods, treatments, and preventive steps work best.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.